Find and Pitch Jounalists, Get Your Story Covered

Tags: Addiction health addiction | drug development | opioids | Pharmaceuticals | public health | STAT Breakthrough Summit art history drug addiction

	Profile	Recent Articles on Subject
1	Ed Silverman STAT News Pharmalot columnist. Senior writer at STATnews. pharmaceutical industry	STAT+: Up and down the ladder: The latest comings and goings - 11 days ago STAT+: Pharmalittle: We’re reading about pharma risks in China, mitigating shortages, and more - 11 days ago STAT+: To mitigate drug shortages, a new study suggests looking at Canada - 12 days ago STAT+: Up and down the ladder: The latest comings and goings - 18 days ago STAT+: Sales from controversial drug discount program rose to $63 billion last year - 25 days ago STAT+: Up and down the ladder: The latest comings and goings - 25 days ago STAT+: Up and down the ladder: The latest comings and goings - about 1 month ago STAT+: Up and down the ladder: The latest comings and goings - 2 months ago STAT+: Pharmalittle: We’re reading about Moderna R&D cuts, Lilly plant investments and more - 2 months ago STAT+: Up and down the ladder: The latest comings and goings - 3 months ago STAT+: Pharmalittle: We’re reading about Zepbound trial results, an Alnylam heart drug, and more - 3 months ago STAT+: Up and down the ladder: The latest comings and goings - 3 months ago STAT+: Up and down the ladder: The latest comings and goings - 3 months ago STAT+: Pharmalittle: We’re reading about Roche obesity drug data, fallout from the Menendez verdict, and more - 4 months ago STAT+: Up and down the ladder: The latest comings and goings - 4 months ago STAT+: Up and down the ladder: The latest comings and goings - 5 months ago STAT+: Up and down the ladder: The latest comings and goings - 6 months ago STAT+: Pharmalittle: We’re reading about an Amgen obesity drug, a Senate bill on shortages, and more - 6 months ago STAT+: Up and down the ladder: The latest comings and goings - 7 months ago STAT+: Pharmalittle: We’re reading about biotech startups, Pfizer’s RSV vaccine, and more - 7 months ago STAT+: Up and down the ladder: The latest comings and goings - 7 months ago STAT+: Up and down the ladder: The latest comings and goings - 8 months ago STAT+: Pharmalittle: We’re reading about a Lilly obesity-drug ad, a $35 cap on inhalers, and more - 8 months ago STAT+: Oregon suspends a portion of its drug transparency law found to be unconstitutional - 9 months ago STAT+: Pharmalittle: We’re reading about slow uptake of an Alzheimer’s drug, an opioid lawsuit, and more - 9 months ago STAT+: Pharmalittle: We’re reading about Lilly selling drugs directly, UCB leaving BIO, and more news - 10 months ago STAT+: FDA is blasted by advocates for pursuing a deal with data provider that has ties to opioid makers - 10 months ago STAT+: Pharmalittle: FDA approvals rebound, abortion pill orders rise, and more news - 10 months ago
2	Adam Feuerstein STAT News Reporter at STATnews. Dog lover. Polk Award winner. Boston, Massachusetts biotech reporting	Biotech’s next gold rush, GLP-1 shortages, and STAT Summit highlights - 26 days ago Summit’s upcoming cancer results, Recursion’s mixed data, and the next big obesity target - 2 months ago STAT+: Summit Therapeutics vs. Merck: Prepping for a big lung cancer study reveal - 2 months ago Listen: Live! From the STAT Breakthrough Summit East - 8 months ago STAT Virtual Event \| Cancer’s Breakthrough Engine - 11 months ago
3	Allison DeAngelis STAT News Reporter at STAT. Formerly Insider, BBJ. biopharmastartupsventure capital	Biotech’s next gold rush, GLP-1 shortages, and STAT Summit highlights - 26 days ago Summit’s upcoming cancer results, Recursion’s mixed data, and the next big obesity target - 2 months ago Listen: Live! From the STAT Breakthrough Summit East - 8 months ago
4	Elaine Chen STAT News Reporter at STATnews. Formerly at Business Insider. Chicago, Illinois journalism	Biotech’s next gold rush, GLP-1 shortages, and STAT Summit highlights - 26 days ago More evidence on GLP-1s and opioid addiction - 26 days ago Summit’s upcoming cancer results, Recursion’s mixed data, and the next big obesity target - 2 months ago
5	Theresa Gaffney STAT News Audio producer, health reporter. Boston audio productionhealth reporting	Morning Rounds: Highlights from the STAT Summit - 26 days ago
6	Meagan Parrish Pharma Voice Senior editor @industrydive. Pharma world follower. Wisconsin, USA pharmaceuticalsjournalismparenting	2024 PharmaVoice 100s: Trailblazers - 27 days ago Pharma execs sound off on trends and policies they’re tracking in 2024 - 10 months ago PharmaVoice’s Crystal Ball: What’s next in drug innovation and clinical trials - 10 months ago
7	Emily Olsen Healthcare Dive Reporter at Healthcare Dive. Loyola, Medill alum. Chicago, Illinois HealthcareNews	Lawmakers urge Biden administration to extend telehealth prescribing flexibilities for opioid use disorder - about 1 month ago
8	Meghana Keshavan STAT News Biotech nerd and writer @statnews. biotechwriting	STAT+: Rick Doblin, ‘unleashed,’ blasts FDA over Lykos drug rejection and turns to global push for MDMA therapy - 3 months ago STAT+: More tumult at BIO amid the company’s fourth CEO in four years - 6 months ago
9	Kennedy Ferruggia, Assistant Editor Pharmacy Times #pharmacy news, insights. CE provider. Cranbury, New Jersey pharmacyhealthcarejournalism	Conference Recap: McKesson ideaShare - 3 months ago McKesson Shares New Initiative to Support Advocacy Efforts for the Pharmacy Profession - 4 months ago
10	Amy Baxter Pharma Voice Scientist, inventor, former pediatrician. Atlanta, Georgia pain relieftechnologyinnovation	Autobahn’s road to a breakthrough depression treatment is paved with high-profile investors - 3 months ago

Journalists covering addiction | drug development | opioids | Pharmaceuticals | public health | STAT Breakthrough Summit